Bio-Techne Secures $12 Million Funding for Thriving Biotech Ventures

Bio-Techne, a leading global developer and manufacturer based in Minneapolis, Minnesota, is proud to announce its recent funding achievement of $12 million, aimed at further enhancing its extensive catalog of over 500,000 high-quality reagents, analytical instruments, and precision diagnostics. With a robust workforce of over 3,000 employees across 34 international locations, Bio-Techne has solidified its position as a pivotal player in the life sciences sector since its inception in 1981 as R&D Systems, transitioning to its current brand in 2014. This substantial funding will be strategically utilized to bolster research and development efforts, driving innovation across its renowned brands including ACD, ExosomeDx, and Tocris Bioscience. The capital infusion comes on the heels of a remarkable fiscal year 2023, during which Bio-Techne reported net sales exceeding $1.1 billion, underscoring the company’s strong market presence and commitment to excellence. The funding will also facilitate Bio-Techne’s continued expansion into emerging markets and the diversification of its customer base, which is critical to sustaining its growth trajectory. With this investment, Bio-Techne reaffirms its commitment to advancing scientific research and providing cutting-edge solutions that empower researchers and healthcare professionals worldwide. As the company forges ahead, it remains dedicated to its mission of delivering superior products that enhance the pursuit of breakthroughs in science and medicine, positioning itself as a trusted partner in the global healthcare ecosystem.